Analyst firms · UBS · BRKR

UBS BRKR price target and rating history

Bruker Corporation (BRKR) · Health Care

UBS rates Bruker Corporation (BRKR) Neutral with a $65 price target, as of its latest action on Sep 9, 2026. It has published 3 rating actions on BRKR since October 2022, including 0 upgrades and 0 downgrades. Across 4 firms with a BRKR price target in the last 12 months, the median target is $60. UBS's $65 is 8% above that.

Current rating
Neutral
Price target
$65
Median target, all firms
$60
Actions on BRKR
3

UBS price target on BRKR

$70$68$652023202420252026
UBS price target on BRKR, each point a stated target, October 2022 to September 2026.

Every UBS rating on BRKR

How other firms rate BRKR

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
UBSNeutral$65Sep 9, 2026
Wolfe ResearchPeer Perform$60Jun 2, 2026
Goldman SachsSell$40Dec 9, 2025
Rothschild & Co RedburnBuy$60Nov 20, 2025

Questions about UBS and BRKR

What is UBS's price target for BRKR?
UBS's latest stated price target for Bruker Corporation (BRKR) is $65, from its action on Sep 9, 2026.
What is UBS's rating on BRKR?
UBS rates BRKR Neutral, a neutral rating, as of Sep 9, 2026.
When did UBS last change its view on BRKR?
On Sep 9, 2026, UBS starts coverage at Neutral, price target $65.
How does UBS's BRKR target compare with other analysts?
Across 4 firms with a BRKR price target in the last 12 months, the median target is $60. UBS's $65 is 8% above that.

More BRKR rating histories

All UBS ratingsBRKR news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.